Skye Bioscience, Inc. (SKYE)
1.16
+0.02
(+1.75%)
USD |
NASDAQ |
Dec 11, 11:55
Skye Bioscience Cash from Financing (Quarterly): 0.00 for Sept. 30, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 0.213M |
| Theravance Biopharma, Inc. | -0.40M |
| Viking Therapeutics, Inc. | 0.48M |
| FibroGen, Inc. | -85.92M |
| Myomo, Inc. | -0.05M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -13.36M |
| Cash from Investing (Quarterly) | 7.967M |
| Free Cash Flow | -41.53M |
| Free Cash Flow Per Share (Quarterly) | -0.3369 |
| Free Cash Flow to Equity (Quarterly) | -13.32M |
| Free Cash Flow to Firm (Quarterly) | -13.36M |
| Free Cash Flow Yield | -90.09% |